Identification of β-Secretase (BACE1) Substrates Using Quantitative Proteomics
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Beta-site APP cleaving enzyme 1 (BACE1) is a transmembrane aspartyl protease with a lumenal active site that sheds the ectodomains of membrane proteins through juxtamembrane proteolysis. BACE1 has been studied principally for its role in Alzheimer's disease as the beta-secretase responsible for generating the amyloid-beta protein. Emerging evidence from mouse models has identified the importance of BACE1 in myelination and cognitive performance. However, the substrates that BACE1 processes to regulate these functions are unknown, and to date only a few beta-secretase substrates have been identified through candidate-based studies. Using an unbiased approach to substrate identification, we performed quantitative proteomic analysis of two human epithelial cell lines stably expressing BACE1 and identified 68 putative beta-secretase substrates, a number of which we validated in a cell culture system. The vast majority were of type I transmembrane topology, although one was type II and three were GPI-linked proteins. Intriguingly, a preponderance of these proteins are involved in contact-dependent intercellular communication or serve as receptors and have recognized roles in the nervous system and other organs. No consistent sequence motif predicting BACE1 cleavage was identified in substrates versus non-substrates. These findings expand our understanding of the proteins and cellular processes that BACE1 may regulate, and suggest possible mechanisms of toxicity arising from chronic BACE1 inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Numerous BACE1 substrates have been identified [30, 55, 123] and others will likely be discovered in the future.”
From The Alzheimer’s β-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques (2013) · cites this paper as [30]
In the citing paper
“However, the numerous BACE1 substrates [30, 55, 123] and complex phenotypes of BACE1 null mice suggest that the inhibition of BACE1 for AD may not be free of mechanism-based toxicity.”
From The Alzheimer’s β-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques (2013) · cites this paper as [30]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063 · cited 1×
“Accumulation and deposition of the amyloid-b (Ab) protein is thought to be a precipitating factor driving disease pathogenesis [2].”
BackgroundSelf-citationElias, J. E., & Gygi, S. P. (2007) · Nature Methods · doi:10.1038/nmeth1019 · Cited by 3,925 · cited 1×
“Resulting MS/MS spectra were matched to a composite target-decoy [55] human sequence database [56], using both SEQUEST and Mascot search engines.”
MethodSelf-citationVassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876
Purification and cloning of amyloid precursor protein β-secretase from human brain
Sinha, S., Anderson, J. P., Barbour, R., Basi, G. S., Caccavello, R., Davis, D., Doan, M., Dovey, H. F., Frigon, N., Hong, J., et al. (1999) · Nature · doi:10.1038/990114 · Cited by 1,612
Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity
Yan, R., Bienkowski, M. J., Shuck, M. E., Miao, H., Tory, M. C., Pauley, A. M., Brashler, J. R., Stratman, N. C., Mathews, W. R., Buhl, A. E., et al. (1999) · Nature · doi:10.1038/990107 · Cited by 1,438
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397 · cited 1×
“. Aβ is known to be a toxic stimulus in a variety of model systems, and emerging experimental and clinical attempts to intervene in the disease process have shown preliminary success by preventing the production or enhancing clearance of the Aβ peptide”
BackgroundClinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329 · cited 1×
“Ab is known to be a toxic stimulus in a variety of model systems, and emerging experimental and clinical attempts to intervene in the disease process have shown preliminary success by preventing the production or enhancing clearance of the Ab peptide [3,4,5,6].”
BackgroundLuo, Y., Bolon, B., Kahn, S., Bennett, B. D., Babu-Khan, S., Denis, P., Fan, W., Kha, H., Zhang, J., Gong, Y., et al. (2001) · Nature Neuroscience · doi:10.1038/85059 · Cited by 1,001
Control of Peripheral Nerve Myelination by the ß-Secretase BACE1
Willem, M., Garratt, A. N., Novak, B., Citron, M., Kaufmann, S., Rittger, A., DeStrooper, B., Saftig, P., Birchmeier, C., & Haass, C. (2006) · Science · doi:10.1126/science.1132341 · Cited by 703
Bace1 modulates myelination in the central and peripheral nervous system
Hu, X., Hicks, C. W., He, W., Wong, P., Macklin, W. B., Trapp, B. D., & Yan, R. (2006) · Nature Neuroscience · doi:10.1038/nn1797 · Cited by 608 · cited 1×
“Previously, twelve proteins have been implicated as b-secretase substrates [22,26,27,28,29,30,31,32], and we were able to identify five of these (APP, APLP1, APLP2, LRP and DSG2) through our unbiased proteomic methods.”
Background
Cited by
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
“…discovery of many new substrates of b-secretase, including some that are critical for signaling events in both the immature and mature nervous system (Willem et al, 2006; Hemming et al, 2009; Kuhn et al, 2012), raises the possibility of significant adverse events appearing over time in such trials.”
BackgroundSelf-citationNew Insights Into the Pathogenesis of Alzheimer's Disease
Fan, L., Mao, C., Hu, X., Zhang, S., Yang, Z., Hu, Z., Sun, H., Fan, Y., Dong, Y., Yang, J., et al. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2019.01312 · Cited by 344
Lichtenthaler, S. F., Lemberg, M. K., & Fluhrer, R. (2018) · The EMBO Journal · doi:10.15252/embj.201899456 · Cited by 323
Vassar, R., Kuhn, P., Haass, C., Kennedy, M. E., Rajendran, L., Wong, P. C., & Lichtenthaler, S. F. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12715 · Cited by 311
Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons
Kuhn, P., Koroniak, K., Hogl, S., Colombo, A., Zeitschel, U., Willem, M., Volbracht, C., Schepers, U., Imhof, A., Hoffmeister, A., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.173 · Cited by 301
Membrane rafts in Alzheimer's disease beta-amyloid production
Vetrivel, K. S., & Thinakaran, G. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.03.007 · Cited by 247
Kandalepas, P. C., Sadleir, K. R., Eimer, W. A., Zhao, J., Nicholson, D. A., & Vassar, R. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1152-3 · Cited by 240
“Numerous BACE1 substrates have been identified [30, 55, 123] and others will likely be discovered in the future.”
BackgroundThe Neural Cell Adhesion Molecules L1 and CHL1 Are Cleaved by BACE1 Protease in Vivo
Zhou, L., Barão, S., Laga, M., Bockstael, K., Borgers, M., Gijsen, H., Annaert, W., Moechars, D., Mercken, M., Gevaer, K., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.377465 · Cited by 167
BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease
Barão, S., Moechars, D., Lichtenthaler, S. F., & De Strooper, B. (2016) · Trends in Neurosciences · doi:10.1016/j.tins.2016.01.003 · Cited by 158
Hitt, B., Riordan, S. M., Kukreja, L., Eimer, W. A., Rajapaksha, T. W., & Vassar, R. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.415505 · Cited by 143
Bace2 Is a β Cell-Enriched Protease that Regulates Pancreatic β Cell Function and Mass
Esterházy, D., Stützer, I., Wang, H., Rechsteiner, M. P., Beauchamp, J., Döbeli, H., Hilpert, H., Matile, H., Prummer, M., Schmidt, A., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.06.018 · Cited by 135
Alzheimer's Disease Mechanisms and Emerging Roads to Novel Therapeutics
Sala Frigerio, C., & De Strooper, B. (2016) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-070815-014015 · Cited by 116
“BACE1 has multiple substrates beyond APP (Hemming et al. 2009, Kuhn et al. 2012, Zhou et al. 2012), and interfering with its function affects fundamental mechanisms at play during brain development (Barão et al. 2015, Hu et al. 2006, Willem et al. 2006).”
Stützer, I., Selevsek, N., Esterházy, D., Schmidt, A., Aebersold, R., & Stoffel, M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.444703 · Cited by 88
Dislich, B., Wohlrab, F., Bachhuber, T., Müller, S. A., Kuhn, P.-H., Hogl, S., Meyer-Luehmann, M., & Lichtenthaler, S. F. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.041533 · Cited by 85
β-Secretase: its biology as a therapeutic target in diseases
Wang, H., Li, R., & Shen, Y. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.01.008 · Cited by 69
Prabhu, Y., Burgos, P. V., Schindler, C., Farías, G. G., Magadán, J. G., & Bonifacino, J. S. (2012) · Molecular Biology of the Cell · doi:10.1091/mbc.e11-11-0944 · Cited by 68
Olsen, O., Kallop, D. Y., McLaughlin, T., Huntwork-Rodriguez, S., Wu, Z., Duggan, C. D., Simon, D. J., Lu, Y., Easley-Neal, C., Takeda, K., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3522-13.2014 · Cited by 64
Toh, W. H., & Gleeson, P. A. (2016) · Biochemical Journal · doi:10.1042/bcj20160147 · Cited by 62
Neuronal human BACE1 knockin induces systemic diabetes in mice
Plucińska, K., Dekeryte, R., Koss, D., Shearer, K., Mody, N., Whitfield, P. D., Doherty, M. K., Mingarelli, M., Welch, A., Riedel, G., et al. (2016) · Diabetologia · doi:10.1007/s00125-016-3960-1 · Cited by 58
BACE1 activity regulates cell surface contactin-2 levels
Gautam, V., D’Avanzo, C., Hebisch, M., Kovacs, D. M., & Kim, D. Y. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-4 · Cited by 46
A reverse signaling pathway downstream of Sema4A controls cell migration via Scrib
Sun, T., Yang, L., Kaur, H., Pestel, J., Looso, M., Nolte, H., Krasel, C., Heil, D., Krishnan, R. K., Santoni, M.-J., et al. (2017) · Journal of Cell Biology · doi:10.1083/jcb.201602002 · Cited by 44
“The extracellular portion of class 4 semaphorins can be proteolytically cleaved, allowing them to also act as soluble ligands (Wang et al., 2001; Hemming et al., 2009; Fong et al., 2011; Armendáriz et al., 2012; Nakatsuji et al., 2012).”
BackgroundFinding memo: versatile interactions of the VPS10p-Domain receptors in Alzheimer’s disease
Salasova, A., Monti, G., Andersen, O. M., & Nykjaer, A. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00576-2 · Cited by 42
He, W., Hu, J., Xia, Y., & Yan, R. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.579862 · Cited by 41
Dual Inhibitors of AChE and BACE-1 for Reducing Aβ in Alzheimer’s Disease: From In Silico to In Vivo
Stern, N., Gacs, A., Tátrai, E., Flachner, B., Hajdú, I., Dobi, K., Bágyi, I., Dormán, G., Lőrincz, Z., Cseh, S., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113098 · Cited by 35
“However, since BACE-1 has several substrates in addition to APP, which are not to be blocked [24], we suggest testing the effect of partial BACE-1 inhibition by weaker inhibitors, if obtained, which may be very effective despite their lower affinity to the target [23,25].”
BackgroundKim, W., Ma, L., Lomoio, S., Willen, R., Lombardo, S., Dong, J., Haydon, P. G., & Tesco, G. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0239-7 · Cited by 32
Identification of BACE1 cleavage sites in human voltage-gated sodium channel beta 2 subunit
Gersbacher, M. T., Kim, D. Y., Bhattacharyya, R., & Kovacs, D. M. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-61 · Cited by 32
Rudan Njavro, J., Klotz, J., Dislich, B., Wanngren, J., Shmueli, M. D., Herber, J., Kuhn, P., Kumar, R., Koeglsperger, T., Conrad, M., et al. (2020) · The FASEB Journal · doi:10.1096/fj.201902347r · Cited by 28
Is It the Twilight of BACE1 Inhibitors?
Hrabinova, M., Pejchal, J., Kucera, T., Jun, D., Schmidt, M., & Soukup, O. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200503023323 · Cited by 28
“Confirmation of the physiological roles of BACE1 substrates in vitro as well as in vivo may help to understand the complexity of BACE1 functions and may reveal how much its inhibition affects other essential biological processes [83-85].”
BackgroundBACE1 regulates the proliferation and cellular functions of Schwann cells
Hu, X., Hou, H., Bastian, C., He, W., Qiu, S., Ge, Y., Yin, X., Kidd, G. J., Brunet, S., Trapp, B. D., et al. (2017) · Glia · doi:10.1002/glia.23122 · Cited by 27
Schrank, S., McDaid, J., Briggs, C. A., Mustaly-Kalimi, S., Brinks, D., Houcek, A., Singer, O., Bottero, V., Marr, R. A., & Stutzmann, G. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031030 · Cited by 22
Spatiotemporal processing of neural cell adhesion molecules 1 and 2 by BACE1 in vivo
Kim, W., Watanabe, H., Lomoio, S., & Tesco, G. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100372 · Cited by 21
Lefort, R. (2015) · Neurotherapeutics · doi:10.1007/s13311-014-0328-4 · Cited by 17
Metadata
- Authors
- Hemming, M. L., Elias, J. E., Gygi, S. P., & Selkoe, D. J.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-12-29
- Volume
- 4
- Issue
- 12
- Pages
- e8477
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2129422864
- Cited by
- 194
- References
- 16
- FWCI
- 5.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.